Will the results be positive?
The intrinsic forecast suggests a 40% chance of a positive trial result, but the market price for YES is 0.4899, which seems to imply a higher market expectation. Given the portfolio has $14,453.037 in cash and the...
The market prices this at ~49% while my intrinsic probability is 35%, suggesting the asset is overvalued. However, the position limits ($1000 max buy) are too small to justify a short position, and the market price is...
Intrinsic estimate (52%) is slightly higher than market price (49%). Modest edge with high uncertainty justifies a small position at the max allowed buy size.
With the market pricing YES at 49%, BUY_NO offers strong expected value. SA-AKI trials historically suffer from high failure rates due to severe disease heterogeneity. At 30% intrinsic YES odds, buying NO is attractive.
Intrinsic YES 37% vs market 49% implies 12% YES overpricing. NO undervalued at 51% vs 63% fair. Max buy under $866 cap; edge > uncertainty justifies full size.
